Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Nov 07 | 2025Insulet, Altimmune, Gubra, Tandem, and Structure Q3 ’25 Earnings; Cagrisema Data at ObesityWeek 2025; MetaVia and Altimmune MASH Results at AASLD 2025; New Lilly Obesity Asset Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Nov 06 | 2025Novo and Pfizer Up Metsera Bids…Again; Novo/Lilly Strike MFN Deal; Lilly Ph2 Amylin Data; Viking Presents VK2735 Data at ObesityWeek; AstraZeneca Q3 ’25 EarningsPurchase Blast
$599
Posted in: Bolus Insulin, Dual/triple agonist, GLP-1RA, Topics Nov 06 | 2025Pfizer Faces Legal Setback in Metsera Battle, Set to Submit New Bid; MannKind and Biomea Q3 ‘25 EarningsPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Other, Topics Nov 05 | 2025Novo Q3 ’25 Earnings; Lowers FY 2025 Guidance…AgainPurchase Blast
$599
Posted in: Allogeneic, Dual/triple agonist, GLP-1RA, Other, Topics Nov 04 | 2025Pfizer and Novo Up Metsera Bids; Pfizer, Amgen, Madrigal, and Vertex Q3 ’25 Earnings; Hims in Talks with NovoPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Nov 03 | 2025Pfizer/Novo Battle Escalates; Lilly Registers Another ORC Study; New Lilly Orfor Manufacturing Site; GSK Ph3 MASH Program Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Oct 31 | 2025Pfizer/Novo Saga Continues; Dexcom, Merck, AbbVie, Alnylam, and Gilead Q3 ‘25 Earnings; Ascletis Selects Obesity Candidate Purchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Other, Topics Oct 31 | 2025Lilly Q3 ‘25 Earnings; Raises FY 2025 Guidance Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Topics Oct 30 | 2025Novo Initiates Metsera Bidding War Purchase Blast
$599
Posted in: Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucagon, Glucose Monitoring, Insulin Delivery, Other, Topics Oct 29 | 2025Beta Bionics Q3 ’25 Earnings; Lilly Partners with Walmart & Invests in Oral Manufacturing; Tandem Integrates with Libre 3+; More Novo Leadership ChangesPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Oct 28 | 2025Regeneron and Novartis Q3 ‘25 Earnings; More Novo Leadership Changes Purchase Blast
$599
Posted in: GLP-1RA, Other, Topics Oct 27 | 2025Lilly Taps Shaq for OSA Awareness; Biomea Doses First Patient with Oral GLP-1RA; Fibronostics Acquisition for MASH Diagnostics Purchase Blast
$599
Posted in: Other, Topics Oct 24 | 2025Sanofi Q3 ‘25 Earnings; Novo Initiates Ph3 Cagrilintide ProgramPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Oct 23 | 2025Roche and Viking Q3 ‘25 EarningsPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Oct 23 | 2025Terns Discontinues Obesity Program; Lingo Available at Walmart; Roche Partners For CVRM Manufacturing; Biocon Expands US Glargine Partnership; NewAmsterdam Registers Ph3 Study of Obicetrapib FDC and MonotherapyPurchase Blast
$599
Posted in: Dual/triple agonist, Other, Topics Oct 21 | 2025Novo Board Updates; Viking Ph1 Maintenance StudyPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Oct 20 | 2025Rybelsus CVRR Approval; FDA Hands Out First CNPVs, Including Tzield; Novo Hires New SVP; Ascletis Ph2 ASC30 Trial Update; BI Appoints New Obesity and Liver Head Purchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Glucose Monitoring, Other, SGLT2i, Topics Oct 16 | 2025Lilly Ph3 Orfor T2DM Results; Abbott Q3 ’25 Earnings Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Oct 15 | 2025Obesity Spotlight: How Will Lilly Maintain Market Leadership?Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Topics Oct 14 | 2025Kailera Raises $600M for its Ph3 Obesity ProgramPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
